PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

Lucid Diagnostics

Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 International Association of Fire Fighters (IAFF) hosted its first #CheckYourFoodTube event to ensure its at-risk firefighters could be tested for esophageal precancer.

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

PAVmed Inc. (NASDAQ:PAVM ) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Anthony Vendetti - Maxim Group Frank Takkinen - Lake Street Capital Markets Ed Woo - Ascendiant Capital Operator Good morning, ladies and gentlemen. And welcome to the PAVmed First Quarter 2024 Business Update Conference Call [Operator Instructions].

PAVmed Inc. (PAVM) Q1 2024 Earnings Call Transcript

Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be held tomorrow, May 14 th at 8:30 AM EDT NEW YORK , May 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024. Conference Call and Webcast The webcast will take place on Tuesday, May 14, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and First Quarter 2024 Financial Results

Quarterly EsoGuard® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering MolDX pre-submission meeting scheduled for July 17, 2024 Conference call and webcast to be held today, May 13 th at 8:30 AM EDT NEW YORK , May 13, 2024 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2024. Conference Call and Webcast The webcast will take place on Monday, May 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection NEW YORK , May 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophageal cell collection device, which it briefly supplied to third-party institutions for their own research studies, has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publication of one of these studies. EsophaCap is not a commercial Lucid product.

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK , May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million.

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 3, 2024 /PRNewswire/ --  PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, May 14, 2024, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication further strengthens EsoGuard's clinical data supporting ongoing engagement to secure commercial and Medicare payor coverage NEW YORK , May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device . This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK , April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J.

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

NEW YORK , April 29, 2024 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. ECAN, a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research, was founded 15 years ago by Mindy Mintz Mordecai following the tragic death of her husband of esophageal cancer.

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

PAVmed Inc. (PAVM) closed at $2.07 in the latest trading session, marking a -1.43% move from the prior day.

Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today

NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T. The fireside chat will be webcast live and can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by clicking here.

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript

Banc of California

Installed Building Products

Proto Labs

Royal Caribbean Cruises

RCL, PAVM, BANC, PRLB and IBP have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2023.

New Strong Buy Stocks for March 27th

Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio technologies Conference call and webcast to be held tomorrow, March 27 th at 8:30 AM ET NEW YORK , March 26, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the year ended December 31, 2023. Conference Call and Webcast The webcast will be available at the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that EsoGuard is a "powerful screening tool" for esophageal precancer and cancer NEW YORK , March 21, 2024 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that investigators at the Louis Stokes Cleveland Veterans Affairs Medical Center, led by Katarina B. Greer, M.D.

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has launched a wholly owned incubator, PMX, to complete development and commercialization of existing portfolio technologies, including the PortIO™ Implantable Intraosseous Vascular Access Device ("PortIO"), EsoCure™ Esophageal Ablation Device ("EsoCure"), and CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome ("CarpX"). PMX and Hatch Medical, L.L.C.

PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia NEW YORK , March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024—the world's premier meeting for digestive disease professionals. "We are excited that our technologies will be prominently featured in multiple presentations at this year's DDW conference," said Suman Verma, M.D.

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 13, 2024 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, March 27, 2024, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 26, 2024, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that it was notified by the World Trade Center Health Program ("WTCHP") that, due to a clerical error, the EsoGuard® Esophageal DNA test was incorrectly listed as a covered benefit. WTCHP advised Lucid on the further steps required, including engaging directly with its Clinical Centers of Excellence.

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

Contrasts EsoCheck's powerful cell collection capabilities to "cruder, decades-old" technologies during comments on patient access to medical technology innovation NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that its Chairman and Chief Executive Officer, Lishan Aklog, M.D., highlighted Lucid's EsoCheck® Cell Collection Device ("EsoCheck") during testimony before the U.S. House of Representatives' Committee on Small Business.

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

Imperial Petroleum

Performance Shipping

We cannot end the year without adding a few penny stocks to our portfolio to take advantage of the opportunities coming up in the next cycle. Of course, we must rely on our investment thesis and our own analysis, but here I am to tell you a little about these undervalued penny stocks that are worth analyzing and evaluating to add to our portfolio.

The 3 Most Undervalued Penny Stocks to Buy in December

Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK , Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the P rospective REV iew of E sophageal Precancer Detectio N in A T -Risk Patients (PREVENT) Registry, the CL inical U tility of E soGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—the first peer-reviewed publications demonstrating real-world clinical utility of Lucid's EsoGuard® Esophageal DNA test to detect esophageal precancer. The publications are: PREVENT Registries - Englehardt R, Samarasena JB, Bildzukewicz NA, Hamblin R, Lee VT, deGuzman BJ, Aklog L.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock NEW YORK , Dec. 11, 2023 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today provided additional details on the previously announced dividend of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) for PAVmed shareholders. On December 4, 2023, the Company announced that the PAVmed Board of Directors had declared a dividend of approximately 3.3 million shares of Lucid common stock with a record date of January 15, 2024.

News for PAVmed Stock (PAVM)